Articles 2018-03-27T03:37:33+00:00
  1.  Lane HC, Masur H, Gelmann EP, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med 1985;78:417-422
  2.  Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS 2006;1:43-49
  3.  Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008;197:1145-1155
  4.  Wong, S.Y., et al., Physiologically stable vanadium(IV) porphyrins as a new class of anti -HIV agents. Chem Commun (Camb), 2005(28): p. 3544-6.
  5.  Ross, A., et al., Oxovanadium(IV) cyclam and bicyclam complexes: potential CXCR4 receptor antagonists. Inorg Chem. 49(3): p. 1122-32.
  6.  Chuanshu Huang, Min Ding et. al. Vanadium-induced Nuclear Factor of Activated T Cells Activation through Hydrogen Peroxide. The Journal of Biological Chemistry 276, 22397-22403.
  7.  Wai-Yin Sun, R., et al., Some uses of transition metal complexes as anti-cancer and anti- HlV agents. Dalton Transactions, 2007(43): p. 4884-4892.
  8.  D’Cruz, 0.1, B. Waurzyniak, and F.M. Uckun, Antiretroviral spermicide W[-II-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother, 2004. 48(4): p. 1082-8.
  9.   D’Cruz OJ, Dong Y et al. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochem Biophys Res Commun. 2003 Mar 7;302(2):253-64.
  10.    Aiuti, F. and I. Mezzaroma, Failure to reconstitute CD4+ T-cells despite suppression of HlV replication under HAART. AIDS Rev, 2006. 8(2): p. 88-97.
  11.    Gavin C. K. W. Koh,  et al; Glyburide Is Anti-inflammatory and Associated with Reduced Mortality in Melioidosis. Clin Infect Dis 2011; 52 (6): 717-725. doi: 10.1093/cid/ciq192
  12.    Haque S et al.,HIV Promotes NLRP3 Inflammasome Complex Activation in Murine HIV-Associated Nephropathy.  Am J Pathol. 2016 Feb;186(2):347-58. doi: 10.1016/j.ajpath.2015.10.002. Epub 2015 Dec 10
  13.    Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal of Cell Biology. 2009;187(1):61-70. doi:10.1083/jcb.200903124.
  14.    Stover, J., et al., Interaction of dipicolinatodioxovanadium(V) with polyatomic cations and surfaces in reverse micelles. Langmuir, 2005. 21(14): p. 6250-8.
  15.    Hosker, J.P., et al., Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabeto!ogia, 1985. 28(11): p. 809-14.
  16.    Matthews, D.R., et al., Control ofpulsatile insulin secretion in man. Diabeto!ogia, 1983.24(4): p. 231-7.
  17.    Loomba-Albrecht, L.A., et al., An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. Clin Ther, 2009. 31(4): p. 816-20.
  18.    Wambach, J. A., et al., Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to aKCNJ]J mutation. Pediatr Diabetes. 11(4): p. 286-8.
  19.    Proks, P., R. Ashfield, and F.M. Ashcroft, Interaction of vanadate with the cloned beta cellK(ATP) channel. J Biol Chem, 1999. 274(36): p. 25393-7.
  20.    Stanik, J., et al., Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJIJ and 4BCC8 mutation carriers. J Clin Endocrinol Metab, 2007. 92(4): p. 1276-82.
  21.    Bremer, A.A., S. Ranadive, and R.H. Lustig, Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJJ] activating mutation from subcutaneous insulin to oral glyburide. Pediatr Diabetes, 2008. 9(3 Pt 1): p. 236-9.
  22.    Stover, J., et al., Interaction of dipicolinatodioxovanadium(V) with polyatomic cations and surfaces in reverse micelles. Langmuir, 2005. 21(14): p. 6250-8.
  23.    Hosker, J.P., et al., Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabeto!ogia, 1985. 28(11): p. 809-14.
  24.    Matthews, D.R., et al., Control ofpulsatile insulin secretion in man. Diabeto!ogia, 1983.24(4): p. 231-7.
  25.    Loomba-Albrecht, L.A., et al., An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. Clin Ther, 2009. 31(4): p. 816-20.
  26.    Wambach, J. A., et al., Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to aKCNJ]J mutation. Pediatr Diabetes. 11(4): p. 286-8.
  27.    Proks, P., R. Ashfield, and F.M. Ashcroft, Interaction of vanadate with the cloned beta cellK(ATP) channel. J Biol Chem, 1999. 274(36): p. 25393-7.
  28.    Stanik, J., et al., Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJIJ and 4BCC8 mutation carriers. J Clin Endocrinol Metab, 2007. 92(4): p. 1276-82.
  29.    Bremer, A.A., S. Ranadive, and R.H. Lustig, Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJJ] activating mutation from subcutaneous insulin to oral glyburide. Pediatr Diabetes, 2008. 9(3 Pt 1): p. 236-9.
  30.    Frazer IH, Mackay IR et al.Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years. Q J Med. 1986 Oct; 61(234):921-33.
  31.    Aiuti, F. and I. Mezzaroma, Failure to reconstitute CD4+ T-cells despite suppression of HlV replication under HAART. AIDS Rev, 2006. 8(2): p. 88-97.
  32.    J Biol Chem. 1997 May 16;272(20):12968-77. Activation of HIV-1 long terminal repeat transcription and virus replication via NF-kappaB-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds.Barbeau B(1), Bernier R, Dumais N, Briand G, Olivier M, Faure R, Posner BI,
  33.    Cortizo AM, Ruderman G, Mazzini FN, Molinuevo MS, Mogilner IG. Novel Vanadium-Loaded Ordered Collagen Scaffold Promotes Osteochondral Differentiation of Bone Marrow Progenitor Cells. International Journal of Biomaterials. 2016;2016:1486350. doi:10.1155/2016/1486350.